Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RETAIN-2: Neoadjuvant AMVAC + Nivolumab for Muscle-Invasive Bladder Cancer
NCT04506554Phase 2Active, not recruiting
- Sponsor
- Fox Chase Cancer Center
- Start
- Dec 2020
- Primary completion
- May 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in bladder carcinoma, sponsored by Fox Chase Cancer Center. Started Dec 2020; status: active, not recruiting.
02
Drugs
03
Conditions
bladder carcinoma
Beyond the preview
Go deeper on NCT04506554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04506554.